CO 044: LIPID-LOWERING THERAPY EFFECTIVENESS IN A SAMPLE OF COLOMBIAN PATIENTS

J Pharm Pharmacogn Res 2(Suppl. 1): S24, 2014

Special supplement with the abstract book of LATINFARMA 2013

Oral Communication

CO 044: LIPID-LOWERING THERAPY EFFECTIVENESS IN A SAMPLE OF COLOMBIAN PATIENTS

Machado-Alba JE, Murillo MM, Machado ME.

Grupo Investigación Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira, Pereira, Colombia. E-mail: machado@utp.edu.co; jormach66@hotmail.com
Abstract

Objective: To determine the effectiveness of lipid-lowering therapy in a sample of patients affiliated with the Colombian Health System.

Methods: The cross-sectional study was conducted between January 1, 2010 and June 30, 2011. Of a total of 8316 patients, a random sample of 600 people from ten cities was stratified according to dyslipidemia. Information on socio-demographic and anthropometric characteristics, risk factors, pharmacological and laboratory variables were obtained from medical records.

Results: There was a female predominance (56.2%) with a mean age of 65.1 ± 11.5 years in the subjects, and 93.2% had hypertension, 29.0% had diabetes mellitus, and 10.2% had a history of myocardial infarction. The patients were treated with lovastatin alone (84.1%), gemfibrozil (12.3%) at doses below those recommended and atorvastatin (1.8%). In patients with a high cardiovascular risk, 38.6% achieved goals for LDL-C levels (<100 mg/dL), while 49.4% of those with a moderate risk reached the target level (<130 mg/dL). On average, there was a 4.9% reduction in LDL-C. Sex, age, personal history of cardiovascular disease and diabetes mellitus, use of hydrochlorothiazide and poor therapy adherence were statistically associated with a lack of control of dyslipidemia.

Conclusions: Because a lack of control over LDL-C levels occurred in men over 55 years, diabetic patients, or those with a history of cardiovascular disease, who received lower doses of lovastatin or were non-adherent to treatment, it is recommended that the dose be increased based on clearly defined therapeutic objectives and that the presence of comorbidities be assessed, which will then be treated properly.